1. Home
  2. AGEN vs ZH Comparison

AGEN vs ZH Comparison

Compare AGEN & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.03

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Logo Zhihu Inc. (every two of each representing one ordinary share)

ZH

Zhihu Inc. (every two of each representing one ordinary share)

HOLD

Current Price

$3.26

Market Cap

295.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
ZH
Founded
1994
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
274.8M
295.1M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
AGEN
ZH
Price
$7.03
$3.26
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
8.2M
165.6K
Earning Date
05-12-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
1.02
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.34
$20.74
Revenue Growth
89.95
N/A
52 Week Low
$2.71
$2.57
52 Week High
$8.85
$5.55

Technical Indicators

Market Signals
Indicator
AGEN
ZH
Relative Strength Index (RSI) 66.62 52.68
Support Level $3.09 $3.24
Resistance Level $8.70 $3.34
Average True Range (ATR) 0.74 0.08
MACD 0.12 0.00
Stochastic Oscillator 65.22 56.14

Price Performance

Historical Comparison
AGEN
ZH

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About ZH Zhihu Inc. (every two of each representing one ordinary share)

Zhihu Inc is engaged in the operation of one online content community which monetizes through paid membership services, marketing services and other services in the People's Republic of China. It is an online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Its community supports discussions ranging from everyday consumer decisions, such as purchasing products or planning travel, to more specialized areas on professional knowledge, technological developments including artificial intelligence and academic topics. It operates in single segment and its revenues are derived from within the PRC.

Share on Social Networks: